Table 5. Relative incidence of medically attended adverse events of interest in the pre-exposure and risk periods for both COVID-19 vaccine doses by condition and vaccine brand, England, 1 October 2020–12 September 2021 (n = 1,283,570 events including control period).

Condition	Comirnaty		Vaxzevria
Condition	RI	95% CI	RI	95% CI
General / injection site / skin
D1: −7 to −1	0.97	0.92–1.01	0.96	0.92–1.00
D1: 0 to 7	0.98	0.94–1.02	1.07***	1.03–1.11
D2: −7 to −1	0.95*	0.90–0.99	0.98	0.94–1.03
D2: 0 to 7	0.98	0.94–1.03	0.96	0.93–1.01
Gastrointestinal / metabolic / nutrition
D1: −7 to −1	0.89***	0.86–0.93	0.95**	0.91–0.99
D1: 0 to 7	0.87***	0.84–0.91	0.93***	0.90–0.97
D2: −7 to −1	0.88***	0.84–0.92	0.96*	0.92–1.00
D2: 0 to 7	0.87***	0.83–0.90	0.93***	0.89–0.97
Immune / lymphatic
D1: −7 to −1	1.16**	1.04–1.28	1.20***	1.09–1.32
D1: 0 to 7	1.32***	1.20–1.45	1.55***	1.43–1.68
D2: −7 to −1	0.89	0.78–1.01	1.00	0.89–1.11
D2: 0 to 7	1.41***	1.28–1.56	1.07	0.97–1.78
Musculoskeletal
D1: −7 to −1	1.01	0.96–1.06	1.01	0.97–1.05
D1: 0 to 7	0.92***	0.88–0.97	0.87***	0.84–0.91
D2: −7 to −1	0.92**	0.87–0.97	1.06**	102–1.11
D2: 0 to 7	0.97	0.92–1.01	1.00	0.96–1.04
Neurological / psychiatric
D1: −7 to −1	0.99	0.95–1.03	0.94**	0.91–0.98
D1: 0 to 7	0.92***	0.88–0.95	1.00	0.97–1.04
D2: −7 to −1	0.91***	0.87–0.95	0.91***	0.87–0.94
D2: 0 to 7	0.94**	0.90–0.98	1.03	0.99–1.07
Respiratory / ear
D1: −7 to −1	0.91***	0.86–0.95	0.87***	0.83–0.91
D1: 0 to 7	0.87***	0.83–0.91	0.82***	0.79–0.86
D2: −7 to −1	0.89***	0.84–0.93	0.90***	0.86–0.95
D2: 0 to 7	0.93**	0.88–0.97	0.84***	0.80–0.88
Vascular
D1: −7 to −1	0.61	0.27–1.34	0.66	0.38–1.16
D1: 0 to 7	0.88	0.51–1.51	0.77	0.47–1.26
D2: −7 to −1	0.97	0.51–1.82	0.60	0.31–1.17
D2: 0 to 7	1.24	0.72–2.12	0.46*	0.23–0.94

COVID-19: coronavirus disease; D1: vaccine dose 1; D2: vaccine dose 2.

Days –7 to –1 refers to the pre-exposure period and days 0 to 7 refers to the risk period.

Significance is denoted as follows: * p < 0.05, ** p < 0.01, *** p < 0.001. Age centred at 50 years.